ProCE Banner Activity

NADIA: Wk 96 Results With DTG vs DRV/RTV and TDF vs ZDV as Second-line ART in Africa

Slideset Download
Conference Coverage
This trial supports use of DTG + 2 NRTIs as second-line ART, even if NRTIs are predicted to have no activity, but resistance is a concern.

Released: February 18, 2022

Expiration: February 17, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare